Trial Profile

A Phase 3 Clinical Trial to Evaluate ZERVIATE (Cetirizine Ophthalmic Solution, 0.24%) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Apr 2023 According to a NicOx media release, the company has received Priority Review Status for the New Drug Application for ZERVIATE in China. This will accelerate the approval process and potentially the launch of ZERVIATE in China.
14 Apr 2023 According to a NicOx media release, company announced that its Chinese partner Ocumension Therapeutics, has submitted a New Drug Application (NDA) for approval to commercialize ZERVIATE and the approval process is expected to take around 12 months, leading to a potential launch of ZERVIATE in China in 2024.
28 Apr 2022 Status changed from recruiting to completed, according to a NicOx media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com